Literature DB >> 2127343

Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa.

J A Reguera1, F Baquero, J Berenguer, M Martinez-Ferrer, J L Martinez.   

Abstract

Antagonism between fosfomycin and antipseudomonal penicillins, cefotaxime, and ceftriaxone was observed in Pseudomonas aeruginosa RYC212. Fosfomycin, a non-beta-lactam antibiotic that acts on bacterial cell wall synthesis, decreased the expression of penicillin-binding protein 3 and induced beta-lactamase. The antagonistic effect was reduced in the presence of high concentrations of the beta-lactamase inhibitor tazobactam or in fosfomycin-resistant mutants. We suggest that products resulting from fosfomycin cell wall damage could interact with a system that regulates penicillin-binding protein and beta-lactamase production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127343      PMCID: PMC172005          DOI: 10.1128/AAC.34.11.2093

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 2.  Modification of penicillin-binding proteins as mechanisms of beta-lactam resistance.

Authors:  F Malouin; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Binding of a non-beta-lactam antibiotic to penicillin-binding proteins.

Authors:  Y Nozaki; N Katayama; H Ono; S Tsubotani; S Harada; H Okazaki; Y Nakao
Journal:  Nature       Date:  1987 Jan 8-14       Impact factor: 49.962

4.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

5.  Reduction in three iron-regulated outer membrane proteins and protein a by the Escherichia coli K-12 perA mutation.

Authors:  M Lundrigan; C F Earhart
Journal:  J Bacteriol       Date:  1981-05       Impact factor: 3.490

6.  Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology.

Authors:  N A Curtis; D Orr; G W Ross; M G Boulton
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.

Authors:  Y Utsui; S Ohya; T Magaribuchi; M Tajima; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

9.  Kinetics and significance of the activity of the Sabath and Abrahams' beta-lactamase of Pseudomonas aeruginosa against cefotaxime and cefsulodin.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

View more
  9 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Authors:  F Tessier; C Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

Review 3.  Penicillin-binding proteins and bacterial resistance to beta-lactams.

Authors:  N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 4.  Non-canonical mechanisms of antibiotic resistance.

Authors:  J L Martínez; J Blázquez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

5.  Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Krisztina M Papp-Wallace; Elise T Zeiser; Scott A Becka; Steven Park; Brigid M Wilson; Marisa L Winkler; Roshan D'Souza; Indresh Singh; Granger Sutton; Derrick E Fouts; Liang Chen; Barry N Kreiswirth; Evelyn J Ellis-Grosse; George L Drusano; David S Perlin; Robert A Bonomo
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

6.  Antibiotic Resistance in Pseudomonas.

Authors:  Pablo Laborda; Sara Hernando-Amado; José Luis Martínez; Fernando Sanz-García
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

Review 8.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

Review 9.  Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.

Authors:  George G Zhanel; Michael A Zhanel; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-06-25       Impact factor: 2.471

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.